Key Insights

Highlights

Success Rate

50% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

2 terminated out of 4 trials

Success Rate

50.0%

-36.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

50% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (3)

Trial Status

Completed2
Terminated2

Trial Success Rate

50.0%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (4)

Research Network

Activity Timeline